Order online now!

www.rockland.com
tech@rockland.com
+1 484.791.3823

Datasheet for 100-4165S

NFKB p65 Antibody

Overview

Description:	Anti-NFKB p65 (Rel A) (RABBIT) Antibody - 100-4165S
Item No.:	100-4165S
Size:	25 µL
Applications:	ELISA, IHC, WB, ChIP, EMSA, IF, IP
Reactivity:	Human, Mouse
Host Species:	Rabbit

Product Details

Background:	Anti NFkB p65 Antibody recognizes NFKB p65 which is a component of NFKB. NFKB was originally identified as a factor that binds to the immunoglobulin kappa light chain enhancer in B cells. It was subsequently found in non-B cells in an inactive cytoplasmic form consisting of NFkappaB bound to IkappaB. NFkappaB was originally identified as a heterodimeric DNA binding protein complex consisting of p65 (RelA) and p50 (NFKB1) subunits. Other identified subunits include p52 (NFKB2), c-Rel, and RelB. The p65, cRel, and RelB subunits are responsible for transactivation. The p50 and p52 subunits possess DNA binding activity but limited ability to transactivate. p52 has been reported to form transcriptionally active heterodimers with the NFkappaB subunit p65, similar to p50/p65 heterodimers. The heterodimers of p52/p65 and p50/p65 are regulated by physical inactivation in the cytoplasm by IkappaBalpha. Ideal for Cardiovascular , Cell Biology, Immunology, Signal Transduction research.
Synonyms:	rabbit Anti-NFKB p65 antibody, rabbit Anti-Rel A antibody, NFKB, nfkb, NF-kB, NF-kappaB, NFkappaB, Nuclear factor NF-kappa-B p65 subunit
Host Species:	Rabbit
Clonality:	Polyclonal
Format:	Antiserum

Target Details

Gene Name:	RELA
Reactivity:	Human, Mouse

Immunogen Type:	Conjugated Peptide
Immunogen:	NFkB p65 (Rel A) peptide corresponding to a region near the C-terminus of the human protein conjugated to Keyhole Limpet Hemocyanin (KLH).
Purity/Specificity:	This product was prepared from monospecific antiserum by delipidation and defibrination. Anti-NFkB p65 (Rel A) may react non-specifically with other proteins. Control peptide (code #100-4165p) will compete only with the specific reaction of antiserum with the NFkB p65 (Rel A) subunit.
Relevant Links:	• UniProtKB - Q04206 • GeneID - 5970 • NCBI - 223468676

Application Details

Tested Applications:	ELISA, IHC, WB
Suggested Applications:	ChIP, EMSA, IF, IP (Based on references)
Application Note:	Anti-NFkB p65 (Rel A) is tested by immunoblot of human and mouse NFkB p65 (Rel A), immunohistochemistry, and ELISA. This product was also tested in a gel supershift assay, IP, IF, and ChIP and found to be reactive against all p65 (Rel A) containing human, mouse or rat NFkB complexes using 0.5 to 1.0 µl per assay.
Assay Dilutions:	All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.
ChIP:	1 µl/IP
ELISA:	1:5,000
EMSA:	05 µL - 1.0 µL
IF:	User Optimized
IHC:	1:400
IP:	User Optimized
WB:	1:2,000 - 1:5,000

Formulation

Physical State:	Liquid (sterile filtered)
Concentration:	80 mg/mL by Refractometry
Buffer:	None

Preservative:	0.01% (w/v) Sodium Azide
Stabilizer:	None

Shipping & Handling

Shipping Condition:	Dry Ice
Storage Condition:	Store vial at -20° C or below prior to opening. This vial contains a relatively low volume of reagent (25 µL). To minimize loss of volume dilute 1:10 by adding 225 µL of the buffer stated above directly to the vial. Recap, mix thoroughly and briefly centrifuge to collect the volume at the bottom of the vial. Use this intermediate dilution when calculating final dilutions as recommended below. Store the vial at -20°C or below after dilution. Avoid cycles of freezing and thawing.
Expiration:	Expiration date is one (1) year from date of receipt.

Images



ChIP
NF-κB complexes are recruited to the EIF4E promoter and promote transactivation. BJAB cells were stimulated with PMA for 0, 1 or 2 hours and subjected to chromatin immunoprecipitation using antibodies specific for (A) NFKB p65 (p/n 100-4165), (B) cRel, (C) p300 transcription factor (p/n 100-301-176) and phosphorylated Pol II (Ser2/Ser5) (D). Data were normalized to IgG control and represented as fold enrichment with respect to untreated cells. Error bars represent standard deviations from triplicate measurements of a representative experiment. Figure 3. PMID: 23467026



Western Blot

Constitutively active NF-κB regulates eIF4E expression in KM-H2 cells.

(A) EMSA analysis of KM-H2 nuclear extracts using probes corresponding to the κB3 and κB4 sites. Supershift analysis using antibodies against NFKB p65 (p/n 100-4165), NFKB p50 p/n 100-4164), cRel and IgG control as well as competition with consensus cold probe (CCP) were done. Protein/DNA complexes are indicated by arrows and supershifted complexes by arrowheads. Free probe is also shown.

Figure 5. PMID: 23467026



Western Blot

Western Blot and ChIP results using NF-κB. Effects of PKC, p38MAPK or PI3K pathway inhibition on NF-κB subunits nuclear translocation in vitro: THP-1 cells were preincubated for 45 min in the absence or presence of the PKC, p38MAPK or PI3K inhibitor before treatment with NE for 15 min. (A) Nuclear extracts of THP-1 cells were immunoblotted with antibodies to p50, p65 (p/n 100-4165), cRel (p/n 100-4166) and histone-1. The signal intensity was evaluated and is summarized in the bargraphs. Statistical significant differences are indicated (*$p < 0.05$). Data represent the mean ± SD (n = 5). (B) The recruitment of p50, p65 and cRel-subunits to the ICAM-1 promoter was determined using ChIP-assays. Fig 3. PMID: 23114885.



Immunofluorescence Microscopy

P5 inhibits NF-κB nuclear translocation in P. acnes-infected HK cells.

The intracellular distribution of NF-κB was determined by immunofluorescent labeling of NF-κB p65 (green), while nuclei were Hoechst stained (blue): (A) untreated HK cells; (B) HK cells treated with P. acnes; (C) HK cells treated with P. acnes plus P5; HK cells treated with P. acnes plus P4 (D).

Fig 5. PMID: 26197393.



Immunohistochemistry
Immunohistochemistry of NFKB p65 (Rel A) antibody. Tissue: lymphocytes and germinal center cells of the human tonsil. Fixation: formalin fixed paraffin embedded. Antigen retrieval: user optimized. Primary antibody: NFKB p65 (Rel A) antibody at 1:400. Secondary antibody: Peroxidase goat anti-rabbit at (p/n 611-103-122) 1:10,000 for 45 min at RT. Localization: nuclear and occasionally cytoplasmic. Staining: Moderate positive nuclear or cytoplasmic staining was observed in lymphocytes and germinal center cells of the tonsil.



Western Blot
Western Blot of Rabbit anti-NFkB antibody. Marker: Opal Pre-stained ladder (p/n MB-210-0500). Lane 1: HEK293 lysate (p/n W09-000-365). Lane 2: HeLa Lysate (p/n W09-000-364). Lane 3: MCF-7 Lysate (p/n W09-000-360). Lane 4: Jurkat Lysate (p/n W09-000-370). Lane 5: A431 Lysate (p/n W09-000-361). Lane 6: A549 Lysate (p/n W09-001-372). Lane 7: LNCap Lysate (p/n W09-001-GJ9). Lane 8: MOLT-4 Lysate (p/n W09-001-GK2). Lane 9: Ramos Lysate (p/n W09-000-GK4). Lane 10: Raji Lysate (p/n W09-001-368). Lane 11: A-172 Lysate (p/n W09-001-GL5). Lane 12: NIH/3T3 Lysate (p/n W10-000-358). Load: 10 µg per lane. Primary antibody: NFkB antibody at 1:500 overnight at 4C. Secondary antibody: Peroxidase rabbit secondary antibody (p/n 611-103-122) at 1:30,000 for 60 min at RT. Blocking Buffer: 1% Casein-TTBS (p/n MB-082) for 30 min at RT. Predicted/Observed size: 65 kDa for NFkB.



Western Blot
Western Blot of Rabbit anti-NFkB p65 (Rel A) antibody. Lane 1: HeLa cell lysate (p/n W09-000-364). Lane 2: HeLa cell lysate (p/n W09-000-364). Load: 35 µg per lane. Primary antibody: NFkB p65 Rel A antibody at 1:5000 for 2 H at RT. Secondary antibody: Peroxidase rabbit secondary antibody at 1:2000 for 60 min at RT. Block: 5% BLOTTO 2 H at RT. Predicted/Observed size: ~65 kDa, ~65 kDa for NFkb p65 Rel A. Other band(s): None.

References

- Gao T et al. Ameliorating Inflammation in Insulin-resistant Rat Adipose Tissue with Abdominal Massage Regulates SIRT1/NF-κB Signaling. *Cell Biochem Biophys.* (2022)
- Follis RM et al. Metabolic control of sensory neuron survival by the p75 neurotrophin receptor in Schwann cells. *J Neurosci.* (2021)
- Cleary et al. NFκB signaling in alveolar rhabdomyosarcoma. *Disease Models & Mechanisms* (2017)
- Passos E et al. Role of physical exercise on hepatic insulin, glucocorticoid and inflammatory signaling pathways in an animal model of non-alcoholic steatohepatitis. *Life Sci* (2015)
- Ryu, S et al. Suppression of Propionibacterium acnes Infection and the Associated Inflammatory Response by the Antimicrobial Peptide P5 in Mice. *PloS One* (2015)
- Fang IM et al. Chitosan oligosaccharides attenuate ocular inflammation in rats with experimental autoimmune anterior uveitis. *Mediators Inflamm.* (2014)
- Hariri F et al. The eukaryotic translation initiation factor eIF4E is a direct transcriptional target of NF-κB and is aberrantly regulated in acute myeloid leukemia. *Leukimia* (2013)
- Brune M et al. Depletion of the receptor for advanced glycation end products (RAGE) sensitizes towards apoptosis via p53 and p73 posttranslational regulation. *Oncogene* (2013)
- Inaba-Hasegagawa K et al. Rasagiline and selegiline, inhibitors of type B monoamine oxidase, induce type A monoamine oxidase in human SH-SY5Y cells. *J Neural Tranm (Viena).* (2012)
- Djuric Z et al. Targeting activation of specific NF-κB subunits prevents stress-dependent atherothrombotic gene expression. *Mol Med.* (2012)
- Albaghdadi AJH et al. Endometrial receptivity defects and impaired implantation in diabetic NOD mice. *Biol Reprod* (2012)
- Herkenham M et al. Cautionary notes on the use of NF-κB p65 and p50 antibodies for CNS studies. *J Neuroinflammation.* (2011)
- Gonzalez-Velasquez F, Reed JW, Fuseler JW, et al. Activation of brain endothelium by soluble aggregates of the amyloid-β protein involves nuclear factor-κB. *Curr Alzheimer Res.* (2011)
- Limpert et al. Axonal Neuregulin 1 Type III Activates NF-kappa B in Schwann Cells during Myelin Formation. *J Bio Chem.* (2010)
- Begley et al. CXCL5 promotes prostate cancer progression. *Neoplasia* (2008)
- Yoon et al. Protein kinase A-induced phosphorylation of the p65 subunit of nuclear factor-kappaB promotes Schwann cell differentiation into a myelinating phenotype. *J. Neuro.* (2008)
- Lou et al. Glutathione depletion down-regulates tumor necrosis factor alpha-induced NF-kappaB activity via IkappaB kinase-dependent and -independent mechanisms. *J Bio Chem.* (2007)
- Cao et al. NF-kappaB1 (p50) homodimers differentially regulate pro- and anti-inflammatory cytokines in macrophages. *J Bio Chem.* (2006)

- Begley et al. CXCL12 overexpression and secretion by aging fibroblasts enhance human prostate epithelial proliferation in vitro. *Aging Cell.* (2005)
- Gregory et al. Efficient replication by herpes simplex virus type 1 involves activation of the IkappaB kinase-IkappaB-p65 pathway. *J Virol.* (2004)
- Fan et al. Divergent C-terminal transactivation domains of Rel/NF-kappa B proteins are critical determinants of their oncogenic potential in lymphocytes. *Oncogene* (2004)
- Chapman et al. Expression and deoxyribonucleic acid-binding activity of the nuclear factor kappaB family in the human myometrium during pregnancy and labor. *J Clin Endocrinol Metab.* (2004)
- Maruyama W et al. N-Propargyl-1 (R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-κB … *Neurochemistry* (2004)
- Feng B et al. NF-κB inducible genes BCL-X and cyclin E promote immature B-cell proliferation and survival. *Cell Immunol* (2004)
- Haller D et al. Transforming growth factor-beta 1 inhibits non-pathogenic Gram negative bacteria-induced NF-kappa B recruitment to the interleukin-6 gene promoter in intestinal epithelial cells through modulation of histone acetylation. *J Biol Chem.* (2003)
- Cheng et al. Cyclin E and Bcl-xL cooperatively induce cell cycle progression in c-Rel-/- B cells. *Oncogene* (2003)
- Poser et al. Upregulation of HMG1 Leads to Melanoma Inhibitory Activity Expression in Malignant Melanoma Cells and Contributes to Their Malignancy Phenotype. *Mol Cell Biol.* (2003)
- Frost LL et al. Propanil inhibits tumor necrosis factor-α production by reducing nuclear levels of the transcription factor nuclear factor-κB in the macrophage cell line IC-21. *Toxicol Appl Pharmacol.* (2001)
- Holmes-McNary MQ et al. Opposing regulation of choline deficiency-induced apoptosis by p53 and nuclear factor κB. *J Biol Chem* (2001)
- Jobin et al. Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. *J Immunol.* (1999)
- Tsubota K et al. Regulation of human leukocyte antigen expression in human conjunctival epithelium. *Invest Opthalmol Vis Sci.* (1999)
- Miller WE et al. The NPC derived C15 LMP1 protein confers enhanced activation of NF-κB and induction of the EGFR in epithelial cells. *Oncogene* (1998)
- Miller WE et al. Interaction of tumor necrosis factor receptor-associated factor signaling proteins with the latent membrane protein 1 PXQXT motif is essential for induction of epidermal growth factor receptor expression *Mol Cell Biol* (1998)
- View More ...

Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.